Pivotal Phase 3 info Show Denosumab Increased Bone Density all through Skeleton In Non Metastatic Breast Cancer Patients On Adjuvant Inhibitor Therapy
Amgen (NASDAQ:AMGN) announced results of the first Phase 3 pivotal study to complete in the denosumab oncology development program. The study evaluated denosumab’s effect on bone density across the skeleton in women with non-metastatic breast cancer who were receiving adjuvant Aromatase Inhibitor (AI) Therapy.
Original post by Women’s Health / Gynecology News From Medical News Today
Related Articles
Pivotal Phase 3 input Show Denosumab Increased Bone Density At Multiple Skeletal Sites In Early And Later Stage Postmenopausal Women Amgen Reports Positive info At ASCO From Three Studies Of Denosumab In Cancer Patients Zometa(R) Helps Prevent Bone Loss In Breast Cancer Patients On Aromatase Inhibitors, notes Presented At SABCS Denosumab Osteoporosis Study Met Primary And All Secondary Bone Mineral Density Endpoints In A Head-to Head Comparison With Weekly Alendronate Denosumab Achieved Superior Bone Mineral Density Gains In Head-To-Head Trial Versus Weekly Alendronate (Fosamax)
